CA
MRNA icon

CV Advisors’s Moderna MRNA Stock Holding History

CV Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,991
Closed -$319K – 21
2024
Q1 		$319K Hold
2,991
– – 0.18% 17
2023
Q4 		$297K Hold
2,991
– – 0.2% 17
2023
Q3 		$309K Hold
2,991
– – 0.23% 18
2023
Q2 		$363K Hold
2,991
– – 0.27% 16
2023
Q1 		$459K Hold
2,991
– – 0.4% 14
2022
Q4 		$537K Sell
2,991
-3,093
-51% -$506K 0.52% 14
2022
Q3 		$719K Sell
6,084
-1,696
-22% -$257K 0.71% 13
2022
Q2 		$1.11M Sell
7,780
-1,475
-16% -$211K 1.05% 12
2022
Q1 		$1.59M Sell
9,255
-985
-10% -$166K 1.13% 13
2021
Q4 		$2.6M Buy
+10,240
New +$2.99M 1.49% 13

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CV Advisors's MRNA Position: Q2 2024 in Review

CV Advisors sold out of Moderna (MRNA) in Q2 2024, closing a stake of 2,991 shares — an estimated $319K sold.

CV Advisors first reported a position in MRNA in Q4 2021 and held it in 10 quarters. The position peaked at $2.6M in Q4 2021. 954 funds tracked by Wall St. Rank hold MRNA as of Q2 2024.

  • CV Advisors reported no remaining Moderna position as of Q2 2024 after selling out during the quarter.
  • CV Advisors sold 2,991 Moderna shares in Q2 2024, an estimated $319K.
  • CV Advisors first reported a position in Moderna in Q4 2021 and held it in 10 quarters.
  • CV Advisors's Moderna position peaked at $2.6M in Q4 2021.
  • 954 funds tracked by Wall St. Rank held Moderna as of Q2 2024.

Based on CV Advisors's 13F filing for Q2 2024, filed 24 Jul 2024.